Senior Manager, Biostatistics, TMTT

Edwards' transcatheter mitral and tricuspid therapies (TMTT), and specialized cardiologists, are making a meaningful mark on the lives of patients with mitral and tricuspid regurgitation. Mitral and tricuspid regurgitation affect more than 10% of people aged 65 and over in the US, creating a poor quality of life and high mortality rates.